Q3 2024 Viking Therapeutics Inc Earnings Call Transcript
Key Points
- Viking Therapeutics Inc (VKTX) reported positive data from four clinical programs, including VK2735 for obesity and VK2809 for NASH and fibrosis.
- The Phase II VENTURE trial for VK2735 demonstrated significant weight loss, with reductions up to 14.7% from baseline.
- VK2809 achieved its primary and secondary endpoints in the Phase IIb VOYAGE study, showing improvements in NASH resolution and fibrosis.
- The company has a strong financial position with $930 million in cash and equivalents, providing a runway for future clinical milestones.
- Viking Therapeutics Inc (VKTX) is advancing its pipeline with plans for Phase III development of VK2735 and further studies for VK2809 and VK0214.
- Viking Therapeutics Inc (VKTX) reported a net loss of $24.9 million for the third quarter of 2024, an increase from the previous year.
- Research and development expenses increased significantly, driven by manufacturing and clinical study costs.
- General and administrative expenses also rose, primarily due to stock-based compensation and legal services.
- The company faces challenges in scaling up manufacturing capacity for potential commercial production.
- There is uncertainty regarding the regulatory path and potential partnerships for the NASH program with VK2809.
Welcome to the Viking Therapeutics Third Quarter 2021 Financial Results Conference Call. (Operator Instructions) As a reminder, this conference is being recorded today, October 23, 2024. And I would now like to turn the conference over to Viking's Manager of Investor Relations, Stephanie Diaz. Please go ahead, Stephanie.
Hello, and thank you all for participating in today's call. Joining me today is Brian Lian, Viking's President and CEO; and Greg Zante, Viking's CFO. Before we begin, I'd like to caution that comments made during this conference call today, October 23, 2024, will contain forward-looking statements under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements about Viking's expectations regarding its development activities, time lines and milestones. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and adversely and reported results should not be considered as an
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
